Intech Investment Management LLC Invests $871,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Intech Investment Management LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,632 shares of the biopharmaceutical company’s stock, valued at approximately $871,000.

A number of other large investors also recently modified their holdings of the stock. KBC Group NV lifted its stake in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics in the 2nd quarter worth about $76,000. CANADA LIFE ASSURANCE Co increased its stake in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 955 shares during the last quarter. Quest Partners LLC lifted its position in shares of Celldex Therapeutics by 1,364.9% during the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 6,879 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares during the last quarter.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $27.89 on Friday. The company has a 50 day simple moving average of $29.09 and a two-hundred day simple moving average of $34.55. The firm has a market cap of $1.85 billion, a PE ratio of -10.85 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1 year low of $22.93 and a 1 year high of $53.18.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CLDX. Citigroup began coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, November 20th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is currently owned by insiders.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.